GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Short Percentage of Float

X4 Pharmaceuticals (FRA:48Q) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of X4 Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, X4 Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

X4 Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's Short Percentage of Float falls into.


X4 Pharmaceuticals (FRA:48Q) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (FRA:48Q) » Definitions » Short Percentage of Float
Comparable Companies
TALS ANNX PBYI CTXR XBIT INMB TNYA CARM TRVI LBPH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
XFOR:USA 48Q:Germany
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
Website
https://www.x4pharma.com
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream.

X4 Pharmaceuticals (FRA:48Q) Headlines

No Headlines